Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
Rheumatol Int ; 25(7): 543-7, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15662528

ABSTRACT

This case report describes the previously-unreported clinical course of a patient with a so-called incomplete systemic lupus erythematosus (SLE), i.e. symptoms related to one organ system only, together with the presence of ANA. He had an indolent course initially and developed, 6 months after the first symptoms, a severe disease with rapid appearance of major and unusual manifestations. The possibility of fast progression and a grave course of an incomplete SLE should be kept in mind. This report is meant to heighten awareness of such an atypical presentation so that prompt and aggressive immunosuppressive therapy may be instituted.


Subject(s)
Antibodies, Antiphospholipid/immunology , Intestinal Obstruction/diagnosis , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/therapy , Abdomen, Acute/diagnosis , Abdomen, Acute/etiology , Adrenal Cortex Hormones/therapeutic use , Adult , Anticoagulants/therapeutic use , Combined Modality Therapy , Critical Illness , Disease Progression , Follow-Up Studies , Humans , Intestinal Obstruction/etiology , Intestinal Obstruction/surgery , Laparotomy/methods , Male , Risk Assessment
2.
Tumori ; 84(5): 534-9, 1998.
Article in English | MEDLINE | ID: mdl-9862512

ABSTRACT

BACKGROUND: The purpose of the present study was to investigate the therapeutic effectiveness of interleukin-2 (IL-2) and interferon (IFN), either alone or in combination, in comparable groups of patients affected by advanced renal cell carcinoma (RCC). PATIENTS AND METHODS: In order to limit selection biases, treatment was allocated on a random basis. Patients randomized to IL-2 alone were scheduled to receive eight rlL-2 24-hour i.v. infusion cycles, days 1 to 4, at a daily dose of 18 x 10(6) lU/m2 for a total of 25 weeks. Patients randomized to IFN alone were scheduled to receive rIFN-alpha at a daily dose of 6 x 10(6) IU/m2, days 1, 3 and 5, every week for a total of 52 weeks. Patients randomized to the combination of IFN and IL-2 were given the same drugs at the same daily doses for a total of 24 weeks. Drug dose was modified according to toxicity. RESULTS: Twenty-three percent (95% CI:+/-17.5) of patients treated with IL-2 alone showed an objective response to treatment (9% CR). The corresponding figures in patients treated with IFN alone or IFN plus IL-2 were 9% (95% CI:+/-11.9) and 9% (95% CI:+/-11.9), respectively. Complete responses were observed only in patients treated with IL-2. The median duration of response in the IL-2 arm was 18 months (range, 9.5-24). The duration of the two responses achieved by IFN alone was seven and nine months, respectively. The corresponding figures in the two patients responding to the combination of IFN with IL-2 were 19 and 27 months, respectively. Total IL-2 dose appeared to be a major predictor of response. Only a minority of patients experienced grade 3-4 toxicity, the incidence being higher in those treated with IL-2 or IL-2 plus IFN. CONCLUSIONS: Neither IFN nor IL-2 or the combination of the two appear to be very active in patients with advanced RCC, even when trial entry was restricted to patients with relatively indolent disease. This stresses the need for the development of new approaches.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Renal Cell/drug therapy , Interferon-alpha/therapeutic use , Interleukin-2/therapeutic use , Kidney Neoplasms/drug therapy , Adult , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Disease Progression , Drug Administration Schedule , Female , Humans , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Interleukin-2/administration & dosage , Interleukin-2/adverse effects , Male , Middle Aged , Prognosis , Risk Factors , Survival Analysis , Treatment Outcome
3.
Neuropediatrics ; 29(5): 249-53, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9810560

ABSTRACT

We report antiphospholipid antibody positivity in three of a consecutive series of 23 children presenting partial epileptic seizures. There was no clinical or serological evidence of systemic lupus erythematosus or other connective-tissue disease. Neither computed tomography nor magnetic resonance imaging revealed ischemic alteration. The presence of antiphospholipid antibodies in 3/23 children may indicate that immune-mediated neuronal damage could be a pathogenetic mechanism for partial epilepsy.


Subject(s)
Antibodies, Antiphospholipid/blood , Epilepsies, Partial/immunology , Adolescent , Antibodies, Anticardiolipin/blood , Anticonvulsants/therapeutic use , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnosis , Carbamazepine/therapeutic use , Child , Child, Preschool , Drug Therapy, Combination , Electroencephalography , Epilepsies, Partial/drug therapy , Female , Humans , Lupus Coagulation Inhibitor/blood , Male , Prednisone/therapeutic use , Valproic Acid/therapeutic use
4.
Tumori ; 80(3): 246-50, 1994 Jun 30.
Article in English | MEDLINE | ID: mdl-8053086

ABSTRACT

AIMS AND BACKGROUND: The systemic administration of recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells is ineffective in non-small-cell lung cancer (NSCLC). However, there is some evidence that their intrapleural administration could be effective, since it increases the concentrations of the cytokine and the effector cells in the tumor area, thereby obtaining greater antitumor activity. STUDY DESIGN: We report the case of a patient affected by a locally advanced lung adenocarcinoma with pleural effusion (T4 N0 M0-stage IIIb) treated with repetitive courses consisting of a priming continuous i.v. infusion (48 h) of rIL-2 (18 MIU/m2/day) intraplural administration of LAK cells (3-9 x 10(9)/day), in a single daily bolus, for 3 consecutive days and concomitant administration of rIL-2 (1.8-7.2 x 10(6) IU/day), for 5 days. RESULTS: We observed early disappearance of neoplastic cells in the pleural effusion, progressive decrease until disappearance of the pleural effusion, cavitation of the primary lesion during the treatment, and its stabilization for 9 months until progression. Radiologic changes were accompanied by a marked eosinophilia (up to 50 x 10(9)/L), and the intrapleural route of administration of rIL-2 induced a relevant increase in eosinophil count in peripheral blood. Immunologic changes in lymphocyte subpopulation phenotypes were also observed. The performance status of the patient improved, and she was still alive and eupnoic 25 months from the diagnosis and 23 months from the start of treatment. CONCLUSIONS: This case suggests a therapeutic role for intrapleural rIL-2, and we believe that the relationship among intrapleural administration of rIL-2 and LAK cells, the development of peripheral eosinophilia, and clinical response should be further investigated.


Subject(s)
Carcinoma, Non-Small-Cell Lung/therapy , Immunotherapy, Adoptive , Interleukin-2/therapeutic use , Killer Cells, Lymphokine-Activated/immunology , Lung Neoplasms/therapy , Carcinoma, Non-Small-Cell Lung/immunology , Eosinophilia/etiology , Female , Humans , Lung Neoplasms/immunology , Middle Aged , Pleura
5.
Br Heart J ; 71(2): 166-9, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8130026

ABSTRACT

BACKGROUND: Immunotherapy with recombinant interleukin 2 (rIL 2) has been extensively used to treat cancer but its use has been hampered by serious side effects including severe hypotension, arrhythmias, and myocardial infarction. OBJECTIVE: To assess the effects of rIL 2 on human left ventricular function. METHODS: Left ventricular (LV) function was monitored in 22 patients (9 women, 13 men) (mean (SD) age 53 (10) years) undergoing a 120 h continuous intravenous infusion of rIL 2 (18 x 10(6) IU/m2/day) for melanoma (4), renal cell (16), ovarian (1), and colon cancer (1). Radionuclide ventriculography was performed before and 1 h after the end of treatment. Ejection fraction (EF), peak emptying rate (PER), peak filling rate (PFR), and regional left ventricular wall motion were analysed. Heart rate (HR), central venous pressure (CVP), systolic (SBP) and diastolic blood pressures (DBP), the electrocardiogram, and myocardial enzyme concentrations were monitored throughout the study. RESULTS: All variables (mean (SD)) were normal before rIL 2 was given. After rIL 2 administration HR increased significantly from 84 (11) to 125 (18) beats/min (p < 0.0001), SBP fell from 128 (11) to 100 (9) mmHg (p < 0.001) and DBP from 76 (9) to 65 (7) mmHg (p < 0.0001). CVP decreased from 3.70 (3.2) to 1.30 (0.45) cm H2O (p < 0.001). EF (65 (7) to 64 (8%) and PER (3.56 (0.60) to 3.86 (0.83) EDV/s) did not change significantly. PFR decreased significantly at the end of the rIL 2 infusion from 2.68 (0.46) to 2.37 (0.43) EDV/s (p < 0.01). Left ventricular segmental hypokinesia developed in 6 patients. Myocardial enzyme concentrations remained normal throughout the study. CONCLUSIONS: The results of this study confirmed that rIL 2 produces important haemodynamic changes, predominantly related to decreased systemic resistance. However, the observed reduction in PFR in most patients suggested that rIL 2 might exert its action at the level of the heart muscle itself. The localised systolic dysfunction in some patients suggested that rIL 2 might also adversely affect myocardial perfusion.


Subject(s)
Interleukin-2/adverse effects , Neoplasms/therapy , Ventricular Function, Left/drug effects , Blood Pressure/drug effects , Carcinoma, Renal Cell/physiopathology , Carcinoma, Renal Cell/therapy , Colonic Neoplasms/physiopathology , Female , Heart Rate/drug effects , Humans , Interleukin-2/therapeutic use , Kidney Neoplasms/physiopathology , Kidney Neoplasms/therapy , Male , Melanoma/physiopathology , Middle Aged , Ovarian Neoplasms/physiopathology , Radionuclide Ventriculography , Recombinant Proteins/therapeutic use
6.
Eur J Cancer ; 30A(9): 1292-8, 1994.
Article in English | MEDLINE | ID: mdl-7999416

ABSTRACT

Starting from in vitro studies suggesting synergistic antitumour activity against renal cell cancer (RCC) of recombinant interleukin-2 (rIL-2) and alpha-interferon (IFN), a phase II trial was initiated to test the clinical activity of this combination. The two cytokines were administered sequentially, with the aim of reducing the risk of additive toxicity and enhancing the immunological reaction against the tumour. The original treatment schedule consisted of rIL-2 18 x 10(6) U/m2/day by continuous intravenous infusion for 120 h days 1-5, and alpha-IFN 2b, at a flat dose of 9 x 10(6) U by subcutaneous or intramuscular injection thrice in a week, from day 8 to 28. Treatment was planned to be continued for six or more 28-day cycles, depending on clinical response. 12 patients were treated according to this schedule; as some cardiovascular toxicity was experienced in this set of patients, 11 further patients were treated with half-dose rIL-2 (i.e. 9 x 10(6) U/m2/day). 17 out of 23 enrolled patients completed at least one cycle of treatment and were evaluated for response. We observed six major responses [one complete response (CR) + five partial responses (PR)] for an objective response rate of 35% [95% confidence interval (CI) 17-59%]. 5 additional patients achieved stabilisation of disease; one of them reached CR after surgical extirpation of a lung mass. Sites of response included lung, nodes and bone. Duration of response is 12+ months for CR; 17, 16, 12+, 9 and 9 months for PRs. Median survival is 16 months. Response was not significantly different between full-dose and half-dose rIL-2. Considering stable disease (SD) as responses, there seemed to be a higher chance of response for patients with smaller tumour burden (P = 0.032). The toxicity of rIL-2 treatment, mainly cardiovascular, was substantial; 9 patients experienced severe cardiotoxicity, consisting of major arrhythmias, myocardial ischaemia, reduction of ejection fraction measured with heart radionuclide scan, and were excluded from continuing treatment. Other rIL-2-related toxicities forcing exclusion from the study were severe thrombocytopenia (1 case), and generalised exfoliative dermatitis requiring steroids (1 case). Otherwise, treatment was well tolerated; rIL-2-related toxicities promptly recovered after rIL-2 discontinuation in the majority of cases, and no treatment-related deaths were reported. The half-dose rIL-2 regimen was significantly less toxic in terms of hypotension (P = 0.014), fever (P = 0.014), oliguria (P = 0.042), serum creatinine elevation (P = 0.009) and prothrombin time elongation (P = 0.038).(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Carcinoma, Renal Cell/therapy , Interferon-alpha/administration & dosage , Interleukin-2/administration & dosage , Kidney Neoplasms/therapy , Adult , Aged , Female , Heart/drug effects , Humans , Interleukin-2/adverse effects , Male , Middle Aged , Recombinant Proteins/therapeutic use , Remission Induction , Time Factors , Treatment Outcome
7.
Pediatr Neurol ; 9(6): 473-5, 1993.
Article in English | MEDLINE | ID: mdl-7605556

ABSTRACT

The occurrence of lupus anticoagulant and anticardiolipin antibodies was demonstrated in a girl affected by recurrent episodes of visual disturbances, with ophthalmologic evidence of visual impairment and sometimes accompanied by migraine. Systemic lupus erythematosus was excluded on the basis of both clinical and serologic criteria and the diagnosis of primary antiphospholipid syndrome was made. Vascular pathogenesis was suggested by the characteristic symptoms. The serologic demonstration of antiphospholipid antibodies made it possible to relate the illness to an immune-mediated thrombotic tendency. This patient demonstrated that the diagnosis of primary antiphospholipid syndrome must always be considered in focal cerebral or retinal ischemia in childhood.


Subject(s)
Antiphospholipid Syndrome/diagnosis , Ischemic Attack, Transient/diagnosis , Retinal Diseases/diagnosis , Vision Disorders/diagnosis , Antibodies, Anticardiolipin/blood , Antiphospholipid Syndrome/drug therapy , Antiphospholipid Syndrome/immunology , Aspirin/administration & dosage , Child , Diagnosis, Differential , Dose-Response Relationship, Drug , Drug Administration Schedule , Electroretinography/drug effects , Evoked Potentials, Visual/drug effects , Evoked Potentials, Visual/physiology , Female , Follow-Up Studies , Humans , Ischemic Attack, Transient/drug therapy , Ischemic Attack, Transient/immunology , Lupus Coagulation Inhibitor/blood , Prednisone/administration & dosage , Recurrence , Retinal Diseases/drug therapy , Retinal Diseases/immunology , Vision Disorders/drug therapy , Vision Disorders/immunology
9.
Tumori ; 77(4): 339-42, 1991 Aug 31.
Article in English | MEDLINE | ID: mdl-1746057

ABSTRACT

A 63-year-old woman receiving recombinant interleukin-2 (rIL-2) + lymphokine activated killer cells for metastatic renal cell carcinoma developed autoimmune thyroiditis with clinical hypothyroidism and high titer anti-thyroglobulin and anti-microsomal antibodies. The onset of thyroid dysfunction was associated with tumor regression and resulted in complete response at the end of the treatment. Cytologic and cytofluorimetric studies on thyroid tissue showed two distinct populations, mainly consisting of small lymphocytes and large thyrocytes, and the latter expressed MHC class II antigens. After completion of rIL-2 treatment, hypothyroidism gradually decreased until resolution; complete tumor remission lasted 18 months. Mechanisms underlying the association between autoimmune thyroiditis and cancer regression are discussed.


Subject(s)
Carcinoma, Renal Cell/therapy , Immunotherapy, Adoptive , Interleukin-2/adverse effects , Kidney Neoplasms/therapy , Killer Cells, Lymphokine-Activated/immunology , Thyroiditis, Autoimmune/etiology , Histocompatibility Antigens Class II/analysis , Humans , Neoplasm Metastasis , Recombinant Proteins/adverse effects
10.
Eur J Pediatr ; 150(9): 652-5, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1915519

ABSTRACT

We report an unusual case of chronic bilateral dacryo-adenitis in 10-year-old identical twin sisters. Both girls presented with bilateral lacrimal gland enlargement and developed moderate xerophthalmia and keratitis. Both the lacrimal and minor salivary gland biopsies showed a non-granulomatous inflammatory infiltration of mono-nuclear cells. All granulomatous diseases and neoplasms could therefore be ruled out and only Sjögren syndrome and very few other forms of chronic dacryo-adenitis remained as possible diagnoses. Both patients and their parents were evaluated for auto-antibodies. Very low titres of smooth muscle antibodies were found in one, antinuclear antibodies in two and anti-dsDNA antibodies in all four members of the family. Even though the titres of antinuclear and anti-dsDNA antibodies increased in one of the sisters, both patients did not develop any sign or symptom of a systemic connective tissue disease. During the 6 years' follow up, both patients showed persistent tarsal gland enlargement but no other symptoms apart from a moderate xerophthalmia and occasional mild keratitis.


Subject(s)
Dacryocystitis/genetics , Diseases in Twins , Sjogren's Syndrome/genetics , Biopsy , Child , Chronic Disease , Dacryocystitis/immunology , Dacryocystitis/pathology , Female , Humans , Keratitis/complications , Keratitis/genetics , Salivary Glands, Minor/pathology , Twins, Monozygotic , Xerophthalmia/complications , Xerophthalmia/genetics
11.
Int J Addict ; 26(5): 505-13, 1991 May.
Article in English | MEDLINE | ID: mdl-1938007

ABSTRACT

Forty-six heroin abusers were hospitalized and treated with meperidine either alone or in association with clonidine. Meperidine was given orally in rapidly decreasing doses according to three different schedules. The majority of patients (87%) successfully completed the detoxification program. The best meperidine starting posology was 200 mg four times daily, which allowed stoppage of the opioid treatment after gradual reduction of the daily dose in a mean time of 9.5 days. Association with clonidine was not proven to be useful. This study shows that meperidine can be effectively used in rapidly decreasing doses in the pharmacological detoxification treatment of hospitalized heroin addicts.


Subject(s)
Heroin Dependence/rehabilitation , Hospitalization , Meperidine/administration & dosage , Administration, Oral , Adolescent , Adult , Combined Modality Therapy , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Heroin Dependence/psychology , Humans , Male , Middle Aged , Patient Dropouts/psychology , Substance Abuse, Intravenous/rehabilitation
13.
Cancer Immunol Immunother ; 33(2): 128-32, 1991.
Article in English | MEDLINE | ID: mdl-2036660

ABSTRACT

Peripheral blood mononuclear cells, obtained from patients with renal cell cancer and cultured ex vivo, exhibit high natural killer (NK) and lymphokine-activated killer (LAK) activity (also against allogeneic fresh tumour cells), which is transcribed into the hosts' immune status after reinfusion. Phenotypic analysis shows a slight increase in the percentage of CD56+ and CD8+ lymphocytes, while CD4+ lymphocytes decrease slightly. As a sign of activation an increase of cells expressing DR and CD25 antigens is observed. At the peripheral blood level, mononuclear cells show an increase, compared to basal values, of NK and LAK activity, especially at the end of the first infusion cycle. Phenotypic analysis of the patients' PBMC shows a decrease of CD3+CD4+ T lymphocytes and an increase of NK cells (CD3-CD56+CD16+) and of cells expressing activation markers (DR and CD25), particularly evident by the end of the second infusion cycle. Finally, in addition to the changes induced by IL-2 alone, reinfusion of incubated cells results in an activation of CD56+ and LeuM3+ cells.


Subject(s)
Carcinoma, Renal Cell/therapy , Immunotherapy, Adoptive , Interleukin-2/therapeutic use , Kidney Neoplasms/therapy , Killer Cells, Lymphokine-Activated/immunology , Antigens, CD/analysis , Cell Separation , Cells, Cultured , Humans , Phenotype , Recombinant Proteins/therapeutic use
15.
Cancer Immunol Immunother ; 32(3): 161-6, 1990.
Article in English | MEDLINE | ID: mdl-2289209

ABSTRACT

The efficacy of recombinant interleukin-2 (rIL-2) or rIL-2 plus lymphokine-activated killer (LAK) cells in cancer therapy has been demonstrated by several groups both in experimental models in animals and clinical trials in humans, but their effects in vivo have yet to be clarified. Starting February 1988, we have treated 12 patients affected by advanced renal cancer with rIL-2 + LAK cells according to an open, non-randomized, phase II trial. Immediately before each rIL-2 infusion and during the last day of infusion, immunological tests were performed on the patients' peripheral blood mononuclear cells. During rIL-2 infusion we have observed a slight increase of the spontaneous cell proliferation and of natural killer (NK) and LAK activity; phenotypic analysis showed a significant decrease in the CD4+ T-lymphocyte subset, both in percentage and in absolute number. Conversely, before each cycle CD4+ cells increased when compared to basal values. No significant variations were observed in the CD8+ T-lymphocyte subset. Furthermore, a significant increase of the NK cells (CD3- CD56+ CD16+) was evident during rIL-2 infusion.


Subject(s)
Carcinoma, Renal Cell/blood , Interleukin-2/pharmacology , Kidney Neoplasms/blood , Killer Cells, Lymphokine-Activated/immunology , Leukocytes, Mononuclear/immunology , CD4 Antigens/immunology , Carcinoma, Renal Cell/drug therapy , Carcinoma, Renal Cell/immunology , Cell Division/drug effects , Drug Evaluation , Humans , Infusions, Intravenous , Interleukin-2/administration & dosage , Kidney Neoplasms/drug therapy , Kidney Neoplasms/immunology , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/drug effects , Phenotype , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology
17.
J Neurol Neurosurg Psychiatry ; 52(6): 749-54, 1989 Jun.
Article in English | MEDLINE | ID: mdl-2746268

ABSTRACT

Eight patients with stable Behçet's disease were studied by means of multimodality evoked potentials and magnetic resonance imaging to evaluate the possibility of an earlier and objective demonstration of clinical and subclinical Central Nervous System (CNS) involvement. It was shown that both diagnostic techniques are useful for quantitative evaluation of neurological involvement in Behçet's disease; of particular interest was the demonstration of subclinical CNS changes.


Subject(s)
Behcet Syndrome/physiopathology , Brain Damage, Chronic/physiopathology , Electroencephalography , Magnetic Resonance Imaging , Adult , Behcet Syndrome/diagnosis , Brain/physiopathology , Brain Damage, Chronic/diagnosis , Child , Evoked Potentials , Female , Humans , Male , Middle Aged , Reaction Time/physiology
18.
J Neurol Neurosurg Psychiatry ; 52(4): 536-8, 1989 Apr.
Article in English | MEDLINE | ID: mdl-2738598

ABSTRACT

A 56 year old man with acute sensory-motor polyneuropathy associated with mycosis fungoides is described. EMG studies showed diffuse signs of muscle denervation. A skin biopsy specimen showed a lymphocyte infiltration in the dermis, composed of mycosis cells characterised by deep invaginations of the nuclear membrane, and small Pautrier's microabscesses in the epidermis. Sural nerve biopsy revealed endoneurial fibrosis, a decreased number of myelinated fibres and acute axonal degeneration.


Subject(s)
Mycosis Fungoides/pathology , Polyneuropathies/pathology , Skin Neoplasms/pathology , Biopsy , Humans , Male , Middle Aged , Nerve Degeneration , Nerve Fibers, Myelinated/pathology , Skin/pathology , Sural Nerve/pathology
20.
Tumori ; 74(3): 257-60, 1988 Jun 30.
Article in English | MEDLINE | ID: mdl-2969637

ABSTRACT

The structure and function of the human T-cell rearranging gamma gene are not completely understood. Several reports have suggested that this gene rearranges specifically in normal T cells, but the pattern of rearrangement in human lymphoid neoplasms is not clear. Some authors have described the rearrangements of this gene in unmanipulated leukemias as relatively specific for T-derived tumors, whereas others were unable to observe such specificity in malignant lymphomas. The present paper reports the analysis of the structure of the gamma gene in 32 lymphoid samples of different origin, with emphasis on non-T lymphomas. Four out of four T-cell lymphomas had this gene rearranged, whereas none of the 17 cases of B-cell lymphomas, 5 of Hodgkin's disease or 6 of nonneoplastic lesions showed any alterations of the gamma gene. Therefore, our data support the relative specificity of the gamma gene rearrangements in human T-cell malignant proliferations.


Subject(s)
Genes, Immunoglobulin , Hodgkin Disease/genetics , Lymphoma, Non-Hodgkin/genetics , Lymphoma/genetics , Receptors, Antigen, T-Cell/genetics , Humans , Lymph Nodes/ultrastructure , Receptors, Antigen, T-Cell, gamma-delta , T-Lymphocytes
SELECTION OF CITATIONS
SEARCH DETAIL
...